StockTipsArenaBeta

BUY Mankind Pharma Limited — Ashish Bahety, Profitmart Securities

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

byAshish Bahety, Profitmart SecuritiesHorizon: NA (inferred Swing (≤2wk))2 Sept 2026via CNBC Awaaz.

Entry₹2,365.2Inferred
Target₹2,450
Total upside +3.59% (call closed)
Stop lossNot given
At expiry₹2,24616 Sept 2026, 3:30 pm
Expired-5.04%auction close
Follow Ashish Bahety for new calls(34% target hit, 235 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 152 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 16 Sept 2026
5 supporting4 neutral0 opposing
Supports the BUY call (5)

Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targets

NewsEt-Markets·28 Aug · 3w ago

(opens in new tab)

Mankind Pharma inks exclusive deal for two insulin analogues in India

NewsCnbc-Tv18·20 Aug · 4w ago

(opens in new tab)

Mankind Pharma has entered into an exclusive in-licensing agreement for Insulin Degludec and its combination for the Indian market. This strategic move aims to expand the company's product portfolio i

NSE · Press Release·20 Aug · 4w ago

(opens in new tab)

Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. for Insulin Degludec and Insulin Degludec + Aspart Combination in In

BSE · Company Update·20 Aug · 4w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·7 Jul · 2mo ago

Neutral / worth noting (4)

Mankind Pharma Gets 68.21 ESG Rating From Niche99 In Leader Category

NewsGoogle News·16 Sept · today

(opens in new tab)

Mankind Pharma to attend three investor conferences in September 2026

NewsGoogle News·11 Sept · 5d ago

(opens in new tab)

Mankind Pharma to meet investors in Mumbai on June 1-2

NewsGoogle News·11 Sept · 5d ago

(opens in new tab)

Mankind Pharma Limited's Board approved the integration of its wholly owned subsidiary, Bharat Serums and Vaccines Limited, into the company via voluntary liquidation.

NSE · Outcome of Board Meeting·26 Aug · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Ashish Bahety, Profitmart Securities

Every call and its outcome